BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2872592)

  • 1. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.
    Boden G; Ryan IG; Eisenschmid BL; Shelmet JJ; Owen OE
    N Engl J Med; 1986 Jun; 314(26):1686-9. PubMed ID: 2872592
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
    Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA
    Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
    Moattari AR; Cho K; Vinik AI
    Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mixed endocrine tumor of the pancreas (vipoma, glucagonoma). Treatment by somatostatin followed by one of its long-acting analogs].
    Kaloustian E; Guillauseau PJ; Chayvialle JA; Veyssier P; Lallement PY; Latrive JP; Zylberait D; Lubetzki J
    Presse Med; 1987 Dec; 16(44):2217-20. PubMed ID: 2893369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
    Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R
    Digestion; 1989; 42(2):116-20. PubMed ID: 2548911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
    Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
    Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of insulinoma with the somatostatin analog SMS 201-995].
    Gilsanz Peral A; Gómez Balaguer M; Costa Talens P
    Med Clin (Barc); 1988 Apr; 90(15):634-5. PubMed ID: 2899658
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
    Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
    Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome.
    Schmid R; Allescher HD; Schepp W; Hölscher A; Siewert R; Schusdziarra V; Classen M
    Hepatogastroenterology; 1988 Feb; 35(1):34-7. PubMed ID: 2896149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogue SMS 201-995 long term therapy for vipoma.
    Juby LD; Burke DA; Axon AT
    Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vipoma, glucagonoma and the role of Sandostatin.
    Bloom SR
    NATNEWS; 1989 Jul; 26(7):15. PubMed ID: 2550822
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].
    Bouin M; Aoust LD
    Gastroenterol Clin Biol; 2002 Oct; 26(10):926-9. PubMed ID: 12434103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.
    Maton PN; O'Dorisio TM; Howe BA; McArthur KE; Howard JM; Cherner JA; Malarkey TB; Collen MJ; Gardner JD; Jensen RT
    N Engl J Med; 1985 Jan; 312(1):17-21. PubMed ID: 2856888
    [No Abstract]   [Full Text] [Related]  

  • 15. Somatostatin analogue and tissue cultures in the study of a human malignant glucagonoma.
    Ahlman H; Ahlund L; Dahlström A; Grimelius L; Theodorsson E
    J Surg Oncol; 1990 Jul; 44(3):191-9. PubMed ID: 2164620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of glucagonoma syndrome to lomustine.
    Khandekar JD; Sriratana P
    Cancer Treat Rep; 1986 Mar; 70(3):433-4. PubMed ID: 3006914
    [No Abstract]   [Full Text] [Related]  

  • 17. [Successful therapy of VIPoma with the long-acting somatostatin analogue SMS 201-995].
    Maeda M; Niitsu Y; Goto Y; Kogawa K; Watanabe N; Kohgo Y; Urushizaki I
    Nihon Naika Gakkai Zasshi; 1988 Jan; 77(1):86-90. PubMed ID: 2897419
    [No Abstract]   [Full Text] [Related]  

  • 18. The glucagonoma syndrome.
    Bloom SR; Sonksen PH
    J R Soc Med; 1990 Jan; 83(1):60. PubMed ID: 1968103
    [No Abstract]   [Full Text] [Related]  

  • 19. The glucagonoma syndrome.
    Sonksen PH; Bloom SR
    J R Soc Med; 1990 Feb; 83(2):127. PubMed ID: 1969482
    [No Abstract]   [Full Text] [Related]  

  • 20. Regression of metastatic vipoma with somatostatin analogue SMS 201-995.
    Clements D; Elias E
    Lancet; 1985 Apr; 1(8433):874-5. PubMed ID: 2858733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.